Search

Genmab A-S

Închisă

2,206 3.18

Rezumat

Modificarea prețului

24h

Curent

Minim

2138

Maxim

2245

Indicatori cheie

By Trading Economics

Venit

243M

295M

Vânzări

259M

1.2B

P/E

Medie Sector

26.002

56.432

EPS

34.85

Marjă de profit

25.541

Angajați

3,119

EBITDA

216M

431M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-1.49% downside

Dividende

By Acuity

Următoarele câștiguri

5 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

17B

130B

Deschiderea anterioară

2202.82

Închiderea anterioară

2206

Genmab A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 sept. 2026, 23:56 UTC

Akebia Therapeutics Inc shares are higher in after-market trading. Broader market sentiment is affected by a sharp decline in the NY Empire State Manufacturing Index.

15 sept. 2026, 23:56 UTC

Fastly Inc. shares declined after-market, influenced by negative sentiment from the NY Empire State Manufacturing Index's sharp fall. The stock settled lower after a brief recovery.

15 sept. 2026, 23:56 UTC

News

Lululemon Athletica shares are lower in after-market hours amid an investigation into potential securities law violations following a revenue guidance cut.

15 sept. 2026, 23:56 UTC

eHealth Inc. shares were little changed in after-market hours. Broader market sentiment weakened following a significant decline in the NY Empire State Manufacturing Index.

15 sept. 2026, 23:56 UTC

Maxlinear Inc shares are lower in after-market hours, pressured by a sharp decline in the NY Empire State Manufacturing Index, raising economic concerns.

15 sept. 2026, 23:56 UTC

DaVita Inc shares are lower in after-market trading amid negative sentiment following a sharp decline in the NY Empire State Manufacturing Index.

15 sept. 2026, 23:56 UTC

Textron Inc shares are higher in after-market trading, reaching a peak gain following the NY Empire State Manufacturing Index's sharp decline to 7.6 for September.

15 sept. 2026, 23:56 UTC

Bandwidth Inc. shares declined in after-market hours, reflecting negative sentiment tied to a sharp drop in the NY Empire State Manufacturing Index.

15 sept. 2026, 23:52 UTC

Japan's August trade deficit hits -1052.6 billion yen amid ongoing economic challenges and weak yen concerns, raising questions on future monetary policy.

15 sept. 2026, 23:52 UTC

Japan's Exports Expected to Rise 0.182% YoY Amid Cautious Optimism in Global Trade Dynamics

15 sept. 2026, 23:52 UTC

Japan's Machinery Orders Expected to Decline by 2.8% in September, Raising Concerns Over Capital Spending and Business Investment

15 sept. 2026, 23:52 UTC

US Business Inventories MoM Data Release on September 16 Expected to Show Modest 0.3% Increase Amid Inflation and Interest Rate Concerns.

15 sept. 2026, 23:52 UTC

Brazil's Central Bank to announce interest rate decisions on September 21, amid global focus on central bank policies and inflation concerns.

15 sept. 2026, 23:52 UTC

NAHB Housing Market Index for September 2026 Expected at 34.0 Amid Ongoing Builder Confidence Concerns and Slowing Home Construction

15 sept. 2026, 23:52 UTC

U.S. Industrial Production Expected to Rise 0.3% in September Amid Mixed Economic Signals and Global Concerns

15 sept. 2026, 23:51 UTC

Innovative Industrial Properties Inc shares are higher in after-market hours, though no specific company news was identified to explain the movement.

15 sept. 2026, 23:51 UTC

Box Inc shares are higher in after-market hours, continuing a trend of higher closes over the last three sessions. No specific news was identified.

15 sept. 2026, 23:51 UTC

Correlated Moves

Shares of Sunrun Inc. declined in after-market trading, diverging from recent trends amid mixed economic data and rising U.S. crude oil inventories.

15 sept. 2026, 23:51 UTC

Progressive Corp shares declined during after-market hours, reaching a low of -0.61%. No specific news was identified to explain the price movement.

15 sept. 2026, 23:51 UTC

Correlated Moves

Ross Stores Inc shares are higher in after-market trading, reflecting positive sentiment linked to TJX Companies Inc's performance amid increased after-hours activity.

15 sept. 2026, 23:51 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. This marks a shift from recent trends.

15 sept. 2026, 23:51 UTC

Under Armour Inc shares are lower in after-market trading, continuing declines amid inflation concerns linked to rising U.S. crude oil inventories.

15 sept. 2026, 23:51 UTC

Minerals Technologies Inc shares are lower in after-market hours, with no specific news identified. The stock remains below its 20-day moving average.

15 sept. 2026, 23:51 UTC

Editas Medicine Inc shares are higher in after-market trading. No specific company news was identified to explain this price movement.

15 sept. 2026, 23:51 UTC

Correlated Moves

Raymond James Financial shares are higher in after-market trading, aligning with Bank of America's performance despite mixed broader market sentiment.

15 sept. 2026, 23:51 UTC

T-Mobile US Inc shares are higher in after-market hours, continuing a recent upward trend from earlier lows. No specific news was identified for the movement.

15 sept. 2026, 23:46 UTC

Insight Enterprises Inc shares are higher in after-market trading, advancing slightly since Tuesday's close. The stock is positioned above its 20-day moving average.

15 sept. 2026, 23:46 UTC

California Water Service Group shares were roughly flat in after-market hours, remaining about 3.74% below their 20-day moving average.

15 sept. 2026, 23:46 UTC

LeMaitre Vascular Inc. shares are higher in after-market trading, moving within a narrow range since Tuesday's close and remaining near the lower end of their monthly range.

15 sept. 2026, 23:46 UTC

Essential Utilities Inc shares are higher in after-market hours, remaining near the upper end of their one-month trading range. No specific news was identified.

Comparație

Modificare preț

Genmab A-S Așteptări

Obiectiv de preț

By TipRanks

-1.49% jos

Prognoză pe 12 luni

Medie 2,493.35 DKK  -1.49%

Maxim 3,320 DKK

Minim 308.417 DKK

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGenmab A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

7 ratings

3

Cumpărare

2

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat